SeaStar Medical (ICU) to Release Earnings on Wednesday

SeaStar Medical (NASDAQ:ICU) is anticipated to post its Q4 2025 results after the market closes on Wednesday, March 25th. Analysts expect SeaStar Medical to post earnings of ($0.97) per share and revenue of $0.2220 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 4:30 PM ET.

SeaStar Medical Stock Performance

Shares of NASDAQ ICU opened at $2.23 on Monday. SeaStar Medical has a 52-week low of $2.09 and a 52-week high of $25.70. The firm has a 50 day moving average price of $2.49 and a two-hundred day moving average price of $4.23. The stock has a market cap of $8.45 million, a P/E ratio of -0.14 and a beta of -1.04.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on ICU. Maxim Group set a $6.00 price target on shares of SeaStar Medical in a report on Thursday, February 12th. Wall Street Zen raised SeaStar Medical to a “hold” rating in a research report on Saturday, January 10th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SeaStar Medical in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell” and an average target price of $6.00.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. XTX Topco Ltd lifted its position in shares of SeaStar Medical by 395.4% in the 2nd quarter. XTX Topco Ltd now owns 60,983 shares of the company’s stock worth $26,000 after purchasing an additional 48,674 shares during the period. Millennium Management LLC acquired a new stake in shares of SeaStar Medical during the third quarter worth $102,000. Finally, Jane Street Group LLC bought a new position in SeaStar Medical during the fourth quarter worth $30,000. Institutional investors own 1.69% of the company’s stock.

About SeaStar Medical

SeaStar Medical, Inc (NASDAQ: ICU) is a medical device company focused on the development and commercialization of cerebral embolic protection systems for patients undergoing transcatheter aortic valve replacement (TAVR) procedures. The company’s mission is to reduce the risk of stroke and other neurologic events associated with structural heart interventions by capturing or deflecting embolic debris that can travel to the brain during catheter-based therapies.

The company’s flagship product, TriGUARD® 3, is a next-generation embolic deflection device designed to provide coverage of all three cerebral vessels during TAVR.